Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 113 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Advance Malignancies Clear all
Recruiting Phase 2 Interventional

DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY

NCT06749210
View directory record Official record
Conditions
Cancer of the Breast, Chemotherapy-induced Neuropathy
Interventions
Tango
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma

NCT05835154
View directory record Official record
Conditions
Metastatic Sarcoma, Sarcoma
Interventions
Assessment, Questionnaire Administration, Interview, Electronic Health Record Review
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385
View directory record Official record
Conditions
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer, RET-altered Solid Tumors, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Thyroid Diseases, Thyroid Neoplasm, Thyroid Cancer, Papillary, Carcinoma, Neuroendocrine, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasm, Head and Neck Neoplasms, Adenocarcinoma, Papillary, Adenocarcinoma, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neuroendocrine Tumors, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Colonic Neoplasms, Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Disease, Colonic Diseases, Intestinal Disease
Interventions
pralsetinib (BLU-667)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 6, 2026, 10:20 AM EDT
Not yet recruiting Phase 1 Interventional

A Study of CS231295 in Patients With Advanced Solid Tumors

NCT07612488
View directory record Official record
Conditions
Advance Solid Tumors, Advanced Malignant Solid Tumors
Interventions
a small molecular multi-target kinase inhibitor
Drug
Lead sponsor
ThalassaX Therapeutics United States Ltd
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

NCT04208178
View directory record Official record
Conditions
Advanced HER2+Breast Cancer
Interventions
Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Fayetteville, Arkansas • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Completed No phase listed Observational Results available

Evaluating the Impact of Patient-Centered Oncology Care

NCT02110758
View directory record Official record
Conditions
Neoplasms
Interventions
Pilot of Patient-Centered Oncology Care
Other
Lead sponsor
National Committee for Quality Assurance
Other
Eligibility
18 Years and older
Enrollment
125,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 6, 2026, 10:20 AM EDT
Completed No phase listed Observational

An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection

NCT01445145
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 30 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Phase 1 Interventional

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

NCT00423254
View directory record Official record
Conditions
Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary
Interventions
PSMA/PRAME
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Not applicable Interventional Results available

Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly

NCT03609177
View directory record Official record
Conditions
Other Cancer
Interventions
Clinician Communication Skills Training, Advance Care Planning (ACP) Decisions Videos Decisions Aids, Video Declarations (ViDec)
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
13,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 6, 2026, 10:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management

NCT06804395
View directory record Official record
Conditions
Cancer Risk
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
1
States / cities
Totowa, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Recruiting Phase 1 Interventional

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

NCT05238792
View directory record Official record
Conditions
Solid Tumor
Interventions
Tumor-associated antigen-specific T cell (TAA-T)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Not applicable Interventional

Four Conversations RCT

NCT02944344
View directory record Official record
Conditions
Breast Cancer
Interventions
Four Conversations
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 6, 2026, 10:20 AM EDT
Not yet recruiting Not applicable Interventional

Understanding Patient Preferences When Deciding on a Voluntary Musculoskeletal Test

NCT07158892
View directory record Official record
Conditions
Non-traumatic Musculoskeletal Conditions, Carpal Tunnel Syndrome (CTS), Lateral Epicondylitis, Osteoarthritis, Trigger Digit, Dupuytren Contracture, Rotator Cuff Tendinopathy, De Quervain Disease
Interventions
Diagnostic Advance Care Planning Discussion, Informational Statement Only
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Not applicable Interventional Results available

Improving Communication About Serious Illness

NCT01933789
View directory record Official record
Conditions
Critical Illness, Chronic Disease, Terminal Care, Palliative Care, Communication, Advance Care Planning, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, End Stage Liver Disease, Kidney Failure, Chronic
Interventions
Communication Feedback Form for Patients with Serious Illness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
817 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Renton, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Community Health Navigators to Advance Cancer Screening Adherence

NCT06492993
View directory record Official record
Conditions
Cancer, Deafness
Interventions
Education
Other
Lead sponsor
Gallaudet University
Other
Eligibility
45 Years to 80 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07552558
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Interventions
Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
Radiation · Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Terminated Phase 2 Interventional Results available

Oxaliplatin and Topotecan in Advance Ovarian Cancer

NCT00313612
View directory record Official record
Conditions
Recurrent Ovarian Epithelial Cancer
Interventions
oxaliplatin, topotecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2015 · Synced Oct 6, 2026, 10:20 AM EDT
Completed No phase listed Observational

Resilience in East Asian Immigrants for Advance Care Planning Discussions

NCT06035549
View directory record Official record
Conditions
Neoplasms, Advance Care Planning
Interventions
Culturally Tailored Digital Resilience-Building, Semi-structured interviews
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Not applicable Interventional

Community Health Workers and Precision Medicine

NCT04843332
View directory record Official record
Conditions
Cancer, Tumor
Interventions
Community Health Worker Support
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 6, 2026, 10:20 AM EDT
Recruiting Not applicable Interventional

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

NCT06377033
View directory record Official record
Conditions
Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm
Interventions
Behavioral nudge
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Terminated Not applicable Interventional

A Media Communication Intervention to Increase Engagement in Advance Care Planning Among Cancer Patients

NCT04208009
View directory record Official record
Conditions
Advance Care Planning Animated Videos
Interventions
Advance care planning animated videos
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 89 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Not applicable Interventional Results available

PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning

NCT04889144
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Communication Intervention, Best Practice, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
New York, New York • Dallas, Texas • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Not applicable Interventional Results available

Goals of Care Conversations Study

NCT05001009
View directory record Official record
Conditions
Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, End-stage Renal Disease, End-stage Liver Disease, Dementia
Interventions
Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement, High patient engagement
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Palo Alto, California • West Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 6, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Results available

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

NCT02643420
View directory record Official record
Conditions
Neutropenia, Breast Cancer
Interventions
SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
76
States / cities
Glendale, Arizona • Tucson, Arizona • Yuma, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 6, 2026, 10:20 AM EDT